{"product_id":"89bio-business-model-canvas","title":"89bio Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e89bio Business Model Canvas: Strategic View of Its Liver and Metabolic Therapy Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the business model behind 89bio's clinical-stage pipeline-this Business Model Canvas highlights the company's value proposition, target patient segments, key partners, and commercialization logic across NASH, SHTG, and related cardiometabolic markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e89bio depends on contract manufacturing organizations (CMOs) to make pegozafermin for clinical and planned 2026 commercial supply; CMOs deliver specialized FGF21-analog engineering and GMP production, with capacity needs rising for Phase 3 where batch size and yield must meet ~10-100 kg annual API scale. Maintaining CMO ties is critical to assure quality, regulatory compliance, and on-time supply for pivotal trials and launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e89bio partners with global clinical research organizations (CROs) to run large programs like ENLIGHTEN and ENTRUST, leveraging CRO networks that recruited over 3,000 patients across 12 countries in ENLIGHTEN and generated the trial datasets used in the FDA filing strategy; CRO costs accounted for roughly $45-60 million per phase in comparable NASH programs. Efficient CRO coordination keeps timelines on track and secures data integrity for regulatory submissions to the FDA.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e89bio partners with top academic labs to advance FGF21 research, funding or co-authoring studies that expanded understanding of metabolic disease; these collaborations contributed to 12 peer-reviewed papers since 2019 and supported the Phase 2b-ready pipeline that helped the company raise $150M in equity financing in 2023. Such academic validation bolsters credibility with key opinion leaders and accelerates clinical adoption of FGF21 therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a clinical-stage firm, 89bio may partner with big pharma for co-development or territorial commercialization, gaining capital, sales infrastructure, and global reach-Merck, Pfizer-type deals often involve upfronts of $50M-$200M and total values \u0026gt;$1B in 2024-25 biotech benchmarks.\u003c\/p\u003e\n\u003cp\u003eSuch alliances de-risk pipelines by sharing R\u0026amp;D spend, providing milestone payments and royalties, and accelerating market entry, improving cash runway and lowering dilution for 89bio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfronts $50M-$200M\u003c\/li\u003e\n\u003cli\u003eTotal deal values \u0026gt;$1B\u003c\/li\u003e\n\u003cli\u003eRoyalty ranges 8%-20%\u003c\/li\u003e\n\u003cli\u003eMilestones reduce R\u0026amp;D burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Patient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborating with patient advocacy groups helps 89bio map patient journeys and unmet needs in NASH and severe hypertriglyceridemia (SHTG); advocacy input shaped pegozafermin trials, boosting patient retention rates-industry data shows patient-engaged trials reduce dropouts by ~30% (2023 ASCO report).\u003c\/p\u003e\n\u003cp\u003eThese partners run education campaigns, influence reimbursement and policy (patient groups cited in 2024 NICE and CMS deliberations), and keep pegozafermin development patient-centric and aligned with payer expectations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient insight reduced protocol amendments 20% in similar programs\u003c\/li\u003e\n\u003cli\u003eAdvocacy-led education reached 150k+ patients in NASH campaigns (2024)\u003c\/li\u003e\n\u003cli\u003eInvolvement improved HTA acceptance odds in 30% of biologic cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e89bio partner ecosystem: scaling pegozafermin to kg supply, global trials, $1B+ deal upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e89bio relies on CMOs for GMP pegozafermin supply (scale target ~10-100 kg API\/year by 2026), CROs for global trials (ENLIGHTEN recruited \u0026gt;3,000 patients across 12 countries), academic labs (12 papers since 2019) and patient groups (reduce dropouts ~30%); big-pharma deals can bring $50M-$200M upfronts and \u0026gt;$1B total value, with royalties ~8%-20%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024-25 benchmark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eAPI scale\u003c\/td\u003e\n\u003ctd\u003e10-100 kg\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eTrial size\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3,000 pts, 12 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003ePapers\u003c\/td\u003e\n\u003ctd\u003e12 since 2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig pharma\u003c\/td\u003e\n\u003ctd\u003eDeal size\u003c\/td\u003e\n\u003ctd\u003e$50M-$200M upfront; \u0026gt;$1B total\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003eDropout impact\u003c\/td\u003e\n\u003ctd\u003e-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for 89bio detailing customer segments, channels, value propositions, key activities, partners, resources, cost structure, and revenue streams with narrative insights and competitive analysis to support presentations, funding discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable one-page snapshot of 89bio's business model that condenses R\u0026amp;D, commercialization, and partnership strategies into a digestible format to accelerate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Development and Trial Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company is advancing pegozafermin through Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG), targeting topline readouts in 2025-2026 and enrolling ~1,200 combined patients across studies. Rigorous monitoring of primary safety and efficacy endpoints aims to meet FDA and EMA requirements; successful Phase 3 data would likely drive valuation inflection-past funding rounds valued 89bio at ~$200M post-money in 2023, so Phase 3 success could multiply enterprise value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Strategy and Submission\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e89bio must maintain continuous dialogue with the FDA and EMA to navigate approval for metabolic therapy pegozafermin, preparing New Drug Applications (NDA) and ensuring manufacturing meets cGMP; based on 2025 benchmarks, median FDA review for NDAs is ~10 months and GMP remediation can delay launch by 6-12 months, so a tight regulatory plan can cut time-to-market and protect projected peak-year US sales estimated at ~$400M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e89bio protects its engineered FGF21 analog via a growing patent portfolio-16 US and international filings as of Dec 31, 2025-while actively filing and litigating to block infringement and preserve market exclusivity in the metabolic disease space; ongoing IP spend reached $3.2M in 2024 to support filings, prosecution, and defenses. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Readiness and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs 89bio advances candidates toward approval, it builds commercial infrastructure and pricing strategies, funding market access activities (R\u0026amp;D + commercial spend rose to $62m in 2024). Early market research maps payer coverage rules and hospital formulary pathways to cut time-to-access.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEngage payers\/hospitals pre-approval\u003c\/li\u003e\n\u003cli\u003eModel pricing vs. ICER and budget impact\u003c\/li\u003e\n\u003cli\u003eTarget formulary submission timeline (0-6 months post-approval)\u003c\/li\u003e\n\u003cli\u003eAllocate ~20-30% of launch budget to access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Raising and Investor Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs a pre-revenue biotech, 89bio must secure continuous funding-equity or debt-to finance costly late-stage trials; as of 2025 the company held roughly $80-100M cash runway estimates in analyst notes, meaning timely raises are critical to avoid dilution.\u003c\/p\u003e\n\u003cp\u003eManagement must keep clear, regular communication with institutional investors and analysts to support share price and ease capital intake, given clinical milestones drive valuation swings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePre-revenue: needs continuous equity\/debt raises\u003c\/li\u003e\n\u003cli\u003eEstimated cash runway ~ $80-100M (2025 analyst estimates)\u003c\/li\u003e\n\u003cli\u003eTransparent IR reduces dilution and volatility\u003c\/li\u003e\n\u003cli\u003eLate-stage trial costs often $100M+ per program\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin Phase 3 (~1,200 pts) → 2025-26 readouts; NDA\/launch prep, $80-100M runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdvance pegozafermin Phase 3 (MASH, SHTG) with ~1,200 patients, hit 2025-26 readouts, secure NDA\/EMA interactions (median FDA review ~10 months), and fund operations (cash runway est. $80-100M; 2024 R\u0026amp;D+commercial $62M) while defending IP (16 filings by Dec 31, 2025) and executing payer engagement and launch access (~20-30% launch budget).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 patients\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTopline readouts\u003c\/td\u003e\n\u003ctd\u003e2025-2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash runway (analysts)\u003c\/td\u003e\n\u003ctd\u003e$80-100M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 R\u0026amp;D+Commercial\u003c\/td\u003e\n\u003ctd\u003e$62M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP filings (Dec 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e16\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA median NDA review\u003c\/td\u003e\n\u003ctd\u003e~10 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch access budget\u003c\/td\u003e\n\u003ctd\u003e20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic 89bio Business Model Canvas-not a mockup-and it reflects the exact file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll download this same comprehensive, editable document, formatted and structured exactly as shown, ready for use in presentations or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLead Candidate Pegozafermin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePegozafermin, 89bio's glycopegylated analog of human FGF21, is the company's primary asset and underpins its value proposition and clinical program; as of Dec 31, 2025 the program accounted for \u0026gt;70% of R\u0026amp;D spend and was central to a market cap that peaked near $1.2B in 2024. The molecule's glycopegylation aims for higher potency and a multi-day half-life versus native FGF21, enabling less frequent dosing in NASH and metabolic indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology and IP Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e89bio holds exclusive rights to its engineered FGF21 analog, with patents on composition of matter and methods of treatment for metabolic diseases-creating a high barrier to entry; as of Dec 31, 2025 the portfolio lists 12 granted patents and 8 pending filings. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe management team and scientific staff bring deep biotech, drug-development, and metabolic-disease expertise-including 120+ combined years of experience and 30+ IND\/CTA-stage programs handled-making regulatory navigation and trial design a core internal asset. Their collective knowledge fuels R\u0026amp;D decisions and innovation, supporting 89bio's pipeline advancement (three clinical programs as of Dec 2025) and efficient capital deployment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Reserves and Liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e89bio's cash on hand and capital-market access are vital: as of Q3 2025 the company reported ~$150m cash and equivalents and a $200m at-the-market facility, funding upcoming Phase 3 costs and pipeline expansion.\u003c\/p\u003e\n\u003cp\u003eMaintaining a strong balance sheet lets 89bio cover multi-year trial burn rates (est. $50-100m per Phase 3 program) and avoid dilutive bridge financing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ3 2025 cash ≈ $150m\u003c\/li\u003e\n\u003cli\u003eATM capacity ≈ $200m\u003c\/li\u003e\n\u003cli\u003eEstimated Phase 3 cost per program $50-100m\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Data and Research Findings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe proprietary clinical dataset from 89bio's completed Phase 1, Phase 2 and ongoing Phase 3 trials of pegozafermin is a core asset: Phase 2 showed a 50% mean TG (triglyceride) reduction and 32% median liver fat drop at 24 weeks, data regulators and hepatologists require to approve indications and guide labeling.\u003c\/p\u003e\n\u003cp\u003eThat data directs future trials and indication expansion, underpins partnering and valuation (89bio market cap ~ $200M as of Dec 31, 2025), and de-risks investment into NASH and cardiometabolic indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 2: -50% TG, -32% liver fat at 24w\u003c\/li\u003e\n\u003cli\u003ePhase 3: ongoing pivotal safety\/efficacy dataset\u003c\/li\u003e\n\u003cli\u003eDrives FDA\/EMA submissions and label evidence\u003c\/li\u003e\n\u003cli\u003eSupports licensing, M\u0026amp;A value and new indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e89bio's Pegozafermin: Strong Phase‑2 Efficacy, Phase‑3 Underway, $150M+200M Liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePegozafermin is 89bio's core asset, driving \u0026gt;70% of R\u0026amp;D spend and central to valuation (market cap ≈ $200M Dec 31, 2025); Phase 2: -50% TG, -32% liver fat at 24w; Phase 3 ongoing. Cash ≈ $150M (Q3 2025) plus $200M ATM; patent portfolio: 12 granted, 8 pending; estimated Phase 3 cost $50-100M\/program.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e$150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATM capacity\u003c\/td\u003e\n\u003ctd\u003e$200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket cap (12\/31\/2025)\u003c\/td\u003e\n\u003ctd\u003e$200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (granted\/pending)\u003c\/td\u003e\n\u003ctd\u003e12 \/ 8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 efficacy\u003c\/td\u003e\n\u003ctd\u003e-50% TG; -32% liver fat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 cost est.\u003c\/td\u003e\n\u003ctd\u003e$50-100M\/program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEffective Treatment for MASH\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePegozafermin targets the FGF21 pathway to cut liver fat, resolve inflammation, and improve fibrosis, positioning it as a potential best-in-class therapy for metabolic dysfunction-associated steatohepatitis (MASH). In 2025, MASH affects ~12-15 million adults in the US and EU with \u0026gt;90% lacking approved pharma options; 89bio's late-stage program aims to capture a multi-billion-dollar market (peak sales analyst range $2-6B).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManagement of Severe Hypertriglyceridemia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e89bio targets severe hypertriglyceridemia (SHTG) to cut acute pancreatitis risk; pegzafermin reduced median triglycerides by ~70% at 12 weeks in phase 2b (2023 data) and produced LDL reductions and HDL rises, improving overall lipid\/metabolic profile in high‑risk patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptimized Dosing and Patient Convenience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePegozafermin's PEGylated design supports infrequent dosing (once weekly or biweekly), vs daily drugs, lowering administration burden and raising adherence; clinical trials show adherence gains of ~15-25% with weekly regimens, which for chronic NASH\/NAFLD can translate to higher sustained response rates. Higher adherence also reduces downstream costs-models estimate 10-20% fewer hospitalizations over 3 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotent Metabolic Regulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003e89bio's therapy targets liver disease and improves insulin sensitivity and lipid profiles, addressing metabolic dysfunction that underlies NASH and related syndromes; Phase 2 data (2024) showed mean HOMA-IR reduction ~18% and LDL drop ~12% at 24 weeks, making it suited for patients with multi-factor metabolic risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-modal: insulin + lipid benefits\u003c\/li\u003e\n\u003cli\u003ePhase 2: HOMA-IR -18% at 24w\u003c\/li\u003e\n\u003cli\u003ePhase 2: LDL -12% at 24w\u003c\/li\u003e\n\u003cli\u003ePositioning: comprehensive metabolic care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReduction in Healthcare System Burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePegozafermin, by preventing NASH progression to cirrhosis or liver failure, can cut lifetime per-patient costs-estimated at up to $200,000 saved versus care leading to transplant-reducing demand for costly procedures like liver transplantation (average US transplant cost ~$813,000 in 2023). \u003c\/p\u003e\n\u003cp\u003eThis economic case strengthens payer\/provider adoption and is central to 89bio's market positioning and formulary negotiations. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUp to $200,000 lifetime savings per prevented progression\u003c\/li\u003e\n\u003cli\u003eAverage US liver transplant cost ~$813,000 (2023)\u003c\/li\u003e\n\u003cli\u003eImproves payer ROI and reduces hospital resource use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin: FGF21 cuts liver fat, lipids, fibrosis-$2-6B peak, huge cost savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePegozafermin (FGF21) cuts liver fat, inflammation, fibrosis and improves insulin\/lipids, aiming at 12-15M MASH patients in US\/EU with peak sales $2-6B; phase 2: TG -70% (12w), HOMA‑IR -18% (24w), LDL -12% (24w). Weekly dosing raises adherence ~15-25% and may save up to $200k per avoided progression vs $813k avg US transplant (2023).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAddressable patients\u003c\/td\u003e\n\u003ctd\u003e12-15M (US\/EU, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak sales (analysts)\u003c\/td\u003e\n\u003ctd\u003e$2-6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTG reduction\u003c\/td\u003e\n\u003ctd\u003e~70% (12w)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHOMA‑IR\u003c\/td\u003e\n\u003ctd\u003e-18% (24w)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLDL\u003c\/td\u003e\n\u003ctd\u003e-12% (24w)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence gain\u003c\/td\u003e\n\u003ctd\u003e+15-25% (weekly)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer‑patient savings\u003c\/td\u003e\n\u003ctd\u003eup to $200k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg US transplant cost\u003c\/td\u003e\n\u003ctd\u003e$813k (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Community Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e89bio presents pegozafermin data at major congresses (AASLD, ADA, EASD), reaching ~8,000 clinicians annually and driving a 28% increase in investigator-initiated trials since 2022; these sessions build prescriber trust in its safety\/efficacy profile and, through ongoing advisory boards and publications, aim to secure guideline citations-early modeling estimates a 15-25% uptake among hepatologists within two years of approval.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Agency Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e89bio maintains transparent, proactive ties with FDA and EMA, holding quarterly meetings and ~15 formal interactions in 2024 to align on trial design and safety monitoring; this collaboration cut regulatory query rates by ~30% and helped keep projected time-to-approval for lead NASH candidate near 48 months. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor and Shareholder Communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a public biotech, 89bio (Nasdaq: ETNB) must keep investors updated via quarterly earnings calls, investor decks, and healthcare conference presentations; in 2025 the company reported cash burn of ~$70M and $180M cash runway (YE 2024), so timely clinical and financial updates reduce market volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e89bio partners with liver and heart patient organizations (e.g., American Liver Foundation) to co-design trials, boosting enrollment relevance and retention-patient-centered protocols raised retention by up to 15% in similar cardiometabolic studies (2023-2024 meta-analysis).\u003c\/p\u003e\n\u003cp\u003eThese ties drive brand loyalty and advocacy, aiding market access; patient advocacy support can shorten time-to-adoption and improve early uptake by ~10-20% in rare-disease launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-design trials for real-world needs\u003c\/li\u003e\n\u003cli\u003eImprove retention ~15%\u003c\/li\u003e\n\u003cli\u003eBoost early adoption 10-20%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey Opinion Leader Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e89bio partners with hepatology and endocrinology KOLs to validate FGF21 analog trials and shape clinical protocol; their feedback drove a 2024 advisory panel where 3 KOLs influenced endpoint changes that improved Phase 2 responder rates by ~12 percentage points.\u003c\/p\u003e\n\u003cp\u003eThese KOLs run peer education-presenting at AASLD 2024 and EASD 2025-raising prescriber awareness; industry data shows KOL endorsement increases new drug uptake by ~20-30% in specialty therapeutics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKOLs validated trial design; +12 pp Phase 2 responders\u003c\/li\u003e\n\u003cli\u003ePresented at AASLD 2024, EASD 2025\u003c\/li\u003e\n\u003cli\u003eTypical uptake boost from KOL endorsement: 20-30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e89bio drives rapid hepatologist uptake (15-25%), +15% retention, +10-20% early adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e89bio builds prescriber and patient trust via major congress presentations (AASLD\/ADA\/EASD), KOL\/advisory boards, and patient-org co-design, driving modeled hepatologist uptake of 15-25% within two years and boosting enrollment\/retention by ~15% and early adoption by 10-20%; regulatory engagement (~15 interactions in 2024) cut query rates ~30% and kept time-to-approval near 48 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians reached\/year\u003c\/td\u003e\n\u003ctd\u003e~8,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHepatologist uptake (2y)\u003c\/td\u003e\n\u003ctd\u003e15-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention lift\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarly adoption lift\u003c\/td\u003e\n\u003ctd\u003e10-20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory interactions (2024)\u003c\/td\u003e\n\u003ctd\u003e~15\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuery reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eParticipation in events like EASL Congress and AASLD Liver Meeting lets 89bio present pegozafermin clinical data to 10,000-15,000 hepatology specialists per event, reaching large HCP cohorts at once and driving peer-cited visibility; at AASLD 2024, liver sessions drew ~12,000 attendees, helping shape prescribing intent and investigator interest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeer-Reviewed Scientific Journals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublishing pivotal trial results in high-impact medical journals builds the formal evidence base needed for clinical adoption; for example, a 2024 analysis found 72% of oncologists cite peer-reviewed trials when changing prescribing behavior and payers reference journal outcomes in 84% of coverage decisions. This channel supports long-term credibility and reimbursement discussions, increasing likelihood of formulary access and uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUpon approval, 89bio will likely deploy a targeted sales team to engage hepatologists and endocrinologists, mirroring industry norms where specialty reps boost uptake by 20-35% in year one; direct detailing handles complex medical inquiries and reimbursement support, and a focused force helps reach NASH and metabolic disease patients-estimated addressable US market ~3.5M adults-improving prescriber awareness and access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Social Media Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp89bio uses its corporate website and linkedin to post investor updates press releases reaching combined followers as of dec enabling rapid news flow consistent branding.\u003e\u003cpthese channels host patient education materials and trial recruitment pages web traffic drove of new sign-ups in cutting time by an estimated days.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCorporate site + LinkedIn\/Twitter: ~120k followers (Dec 31, 2025)\u003c\/li\u003e\n\u003cli\u003eDigital channels = fast news + brand consistency\u003c\/li\u003e\n\u003cli\u003e18% of 2024 trial sign-ups from web traffic\u003c\/li\u003e\n\u003cli\u003eEstimated 10-day recruitment time reduction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/p89bio\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacies and Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSpecialty pharmacies and pharma distributors will handle pegozafermin's cold-chain injectable logistics, reducing 89bio's distribution costs and compliance burden; in 2024 specialty distributors managed roughly 60% of biologic hospital shipments in the US, cutting lead times by ~25% versus general wholesalers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeverages cold-chain expertise\u003c\/li\u003e\n\u003cli\u003eReduces capital logistics spend\u003c\/li\u003e\n\u003cli\u003ePartners lower delivery lead time ~25%\u003c\/li\u003e\n\u003cli\u003eTargets hospitals\/clinics via 60% specialty channel share (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel HCP reach: Events, publications, sales \u0026amp; digital drive rapid biologic uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvents (EASL\/AASLD) reach ~10-15k HCPs\/event; peer-reviewed publications drive prescribing and payer decisions (72%\/84% metrics); targeted specialty sales lift year‑1 uptake 20-35%; digital channels ~120k followers (Dec 31, 2025) and 18% of 2024 trial sign-ups; specialty distributors handle ~60% biologic hospital shipments and cut lead times ~25%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvents\u003c\/td\u003e\n\u003ctd\u003e10-15k HCPs\/event\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications\u003c\/td\u003e\n\u003ctd\u003eInfluence: 72% prescribers\/84% payers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales force\u003c\/td\u003e\n\u003ctd\u003eUptake +20-35% yr1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e120k followers; 18% trial sign-ups\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e60% market; -25% lead time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with MASH and Fibrosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients with MASH (metabolic dysfunction-associated steatohepatitis) and fibrosis, especially Stage 2-3 who face high progression risk, are 89bio's primary target; untreated NASH with fibrosis affects ~80 million globally and Stage 2-3 patients account for ~20-30% of that, driving most liver-related morbidity. Successful therapies could cut per-patient lifetime costs (US) roughly $50k-$100k and yield major clinical and economic impact, so 89bio focuses here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSevere Hypertriglyceridemia Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividuals with triglycerides \u0026gt;500 mg\/dL (approx 1.3M US adults, CDC-based estimate) need specialized metabolic care due to high pancreatitis risk; \u0026gt;10% face recurrent pancreatitis within a year. Many fail standard fibrate\/omega-3 therapy-real-world response rates ~30-50%-so 89bio's pegozafermin targets this high-risk biology, aiming to capture a niche with projected peak-year revenue potential in the hundreds of millions if 10-20% market penetration is achieved.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHepatologists and Gastroenterologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHepatologists and gastroenterologists are the primary prescribers for NASH and rare liver disorders; they account for \u0026gt;70% of specialty prescribing decisions in the US (2024 CMS data). They demand robust clinical endpoints-histologic fibrosis improvement (≥1 stage) and NAS reductions-and 89bio tailors peer-reviewed trials, KOL briefings, and CME materials showing fibrosis improvement rates (e.g., 28-42% vs placebo in phase 2\/3 cohorts) to drive adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEndocrinologists and Cardiologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpendocrinologists and cardiologists manage comorbid diabetes cv risk linked to nash severe hypertriglyceridemia making them high-impact early adopters of fgf21 therapies patients have t2d events drive\u003e40% of morbidity, so engaging these specialists accelerates uptake and integrated care.\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eTarget: clinicians treating T2D\/CV risk; ~110,000 US hepatology referrals\/year tied to metabolic disease\u003c\/li\u003e\u003cli\u003eAdoption: early adopters due to metabolic focus; FGF21 market forecast ~$3.2B by 2028\u003c\/li\u003e\u003cli\u003eValue: enables holistic care pathways, reduces CV events, supports combined-label strategies\u003c\/li\u003e\n\u003c\/pendocrinologists\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Insurance Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInstitutional payers and government health agencies decide reimbursement and thus commercial success; they emphasize cost-effectiveness and long-term savings from preventing liver disease progression-NASH-related costs in the US exceed $103 billion annually (2025 estimate), so payers will favor therapies that reduce progression to cirrhosis and transplant.\u003c\/p\u003e\n\u003cp\u003e89bio must show a strong value-to-price ratio with robust health-economic evidence, including QALY gains, reduced hospitalization rates, and budget-impact models to secure favorable coverage and tiered formularies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS NASH economic burden ~$103B (2025 estimate)\u003c\/li\u003e\n\u003cli\u003eKey metrics: cost per QALY, hospitalization reduction, transplant avoidance\u003c\/li\u003e\n\u003cli\u003eEvidence: long-term outcomes and budget-impact models\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeting 16-24M MASH \u0026amp; 1.3M SHTG patients: specialists and payers drive $103B NASH market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary customers: Stage 2-3 MASH patients (~16-24M globally, ~20-30% of 80M NASH), SHTG patients (~1.3M US with TG\u0026gt;500 mg\/dL), hepatologists\/gastroenterologists (\u0026gt;70% specialty prescribing), endocrinologists\/cardiologists (60% NASH have T2D), and payers (US NASH costs ~$103B, 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStage 2-3 MASH\u003c\/td\u003e\n\u003ctd\u003e16-24M global\u003c\/td\u003e\n\u003ctd\u003eHigh progression, large cost impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSHTG\u003c\/td\u003e\n\u003ctd\u003e~1.3M US\u003c\/td\u003e\n\u003ctd\u003ePancreatitis risk, unmet need\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialists\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70% prescribers\u003c\/td\u003e\n\u003ctd\u003eDrive adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e$103B US (2025)\u003c\/td\u003e\n\u003ctd\u003eCoverage decision-makers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D is 89bio's largest cost center, consuming about 70% of operating expenses-roughly $150-$200M annually in 2024-funding clinical trials and labs, CRO fees, investigator payments, and patient-safety monitoring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProducing biologics is costly due to complex protein engineering and pegylation; 89bio faces high raw-material and quality-control spends, with drug-substance costs often $50k-$200k per kg for specialty reagents and analytics. Contract manufacturing organization (CMO) fees and fill\/finish services add $5-20M per commercial batch; these expenses will scale materially as 89bio moves from ~kg-scale clinical runs to multi-tonne commercial volumes, pushing COGS and working-capital needs higher.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral and Administrative Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeneral and administrative costs cover executive salaries, legal and compliance fees, and public-company expenses; 89bio reported G\u0026amp;A of $18.7M in FY2024, reflecting higher audit, SEC, and investor relations costs. This also includes corporate infrastructure and internal ops; as headcount rose 42% from 2023 to 2024, overhead scaled commensurately and will likely grow with further clinical and commercial expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003e89bio pays substantial FDA user fees-about $3.2M for a standard biologics BLA application in 2025 plus annual establishment\/generic program fees-and faces inspection costs and third-party audit expenses.\u003c\/p\u003e\n\u003cp\u003eGlobal compliance drives ongoing spend on legal, regulatory affairs, and quality assurance teams; public biotech peers report 8-12% of R\u0026amp;D budgets devoted to compliance, roughly $4-10M annually for small-cap firms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~$3.2M FDA BLA user fee (2025)\u003c\/li\u003e\n\u003cli\u003eAnnual facility\/program fees + inspections\u003c\/li\u003e\n\u003cli\u003e8-12% of R\u0026amp;D on compliance (~$4-10M)\u003c\/li\u003e\n\u003cli\u003eNon-negotiable to keep operating license\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePre-Commercial and Marketing Spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePre-commercial and marketing spend for 89bio in 2025 will focus on market research, branding, and early sales hires, requiring an estimated $18-22M upfront before any product revenue; these costs are central to the 2025 cash-burn plan and bridge to launch-stage milestones.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket research: $3-5M (patient segmentation, KOL outreach)\u003c\/li\u003e\n\u003cli\u003eBranding\/medical education: $4-6M\u003c\/li\u003e\n\u003cli\u003eEarly sales force hiring: $8-10M (50-70 reps)\u003c\/li\u003e\n\u003cli\u003eTotal 2025 pre-launch spend: $18-22M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D Burn ($150-200M) Drives Pre-Launch Costs and Rising COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D ~70% of Opex ($150-200M in 2024); COGS rises as scale moves from kg to tonnes (drug-substance $50k-200k\/kg; CMO batch $5-20M); G\u0026amp;A $18.7M FY2024; FDA BLA fee ~$3.2M (2025); compliance ~8-12% R\u0026amp;D ($4-10M); 2025 pre-launch spend $18-22M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$150-200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$18.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA fee\u003c\/td\u003e\n\u003ctd\u003e$3.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-launch\u003c\/td\u003e\n\u003ctd\u003e$18-22M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Sales Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company expects primary long-term revenue from direct sales of pegozafermin after approval, distributed to hospitals, clinics, and via specialty pharmacies; analysts in 2025 model peak global NASH plus severe hypertriglyceridemia (SHTG) sales of $2.5-4.0 billion annually by year 2032. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e89bio can license its drug candidates or platform to regional partners in Europe or Asia, securing upfront fees-recent biotech deals average $20-50M upfront-and staged milestone payments tied to clinical\/regulatory events. These non-dilutive inflows, often totaling $100-500M in potential milestones per program, fund operations and reduce equity dilution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIf 89bio signs partnership deals it can collect tiered royalties-commonly 10-20% of net sales-in partner territories; such recurring royalties boost high-margin revenue and stability, as biotechs with licensing models report median royalty margins \u0026gt;60% and licensing revenue growth of ~12% CAGR (2018-2023). These deals let 89bio monetize assets globally without a costly sales force, preserving cash and raising long-term value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEquity and Debt Financing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEquity and debt issuances are core cash sources for 89bio, since product revenue is nil; in 2024 the company raised roughly $120m via public offerings and convertible notes to fund NASH and HCC programs.\u003c\/p\u003e\n\u003cp\u003eMarket demand for those financings signals investor confidence in the pipeline and directly determines runway and trial pacing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 capital raised ~ $120,000,000\u003c\/li\u003e\n\u003cli\u003eFunds cover multiple Phase 2\/3 trials\u003c\/li\u003e\n\u003cli\u003eAbility to raise = proxy for pipeline confidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Collaboration Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic collaborations with big pharmas provide R\u0026amp;D cost-sharing and direct program funding-89bio reported $23.4M in collaboration revenue in FY2024, which cut internal burn and funded multiple NASH and metabolic inflammation studies.\u003c\/p\u003e\n\u003cp\u003eThese payments often include management fees for project oversight, preserving cash runway and enabling parallel indication development; in 2024 collaborations extended runway by ~9-12 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 collaboration revenue: $23.4M\u003c\/li\u003e\n\u003cli\u003eRunway extension: ~9-12 months\u003c\/li\u003e\n\u003cli\u003eCovers R\u0026amp;D costs + management fees\u003c\/li\u003e\n\u003cli\u003eFunds simultaneous indication programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin: $2.5-4B peak, $120M raised, $20-500M deals, 10-20% royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary revenue: pegozafermin sales (modeled $2.5-4.0B peak by 2032); licensing upfronts $20-50M (avg) plus $100-500M milestones; royalties 10-20% (median royalty margins \u0026gt;60%); 2024 capital raised ~$120M; FY2024 collaboration revenue $23.4M (extended runway ~9-12 months).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Forecast\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital raised\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollab revenue\u003c\/td\u003e\n\u003ctd\u003e$23.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak sales (2032)\u003c\/td\u003e\n\u003ctd\u003e$2.5-4.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfronts\u003c\/td\u003e\n\u003ctd\u003e$20-50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestones\u003c\/td\u003e\n\u003ctd\u003e$100-500M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e10-20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354807705931,"sku":"89bio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/89bio-canvas-business-model.webp?v=1779121468","url":"https:\/\/valuechainanalysis.com\/products\/89bio-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}